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The COVID-19 Vaccination Race
ROOJIN HABIBI

I was asked to speak about the COVID vaccination race, and I
think it is important to unpack this idea and reflect on what we mean
when we talk about a ‘race’. Who are we really racing against? Many
countries around the world have lost the plot on the global response to
COVID-19, as they remain razor-focused on vaccinating their own
populations as quickly as possible. As the emergence of new variants
of the SARS-CoV-2 virus reveals, however, this is a recipe for disaster.
Before we get to that, though, I do want to begin with a silver
lining to this pandemic, which is that within less than a year, the world
managed to produce several safe and effective vaccines against the
virus that causes COVID-19. This is a no small part thanks to the broad
spirit of international cooperation, scientific research and knowledge
sharing that emerged in the early stages of the pandemic. It is a
laudable and unprecedented feat, and we should continue to finetune
this model to better hone our capacity to develop therapeutics urgently
in response to inevitable new outbreaks that lie around the corner.
Pandemic threats are a fact of life in our modern globalized era.
But the picture of human solidarity rising up against a common
threat ends there; almost as soon as vaccines entered the market,
countries began bidding against one another to procure access to these
lifesaving innovations. The handful of higher income countries that
had the means to do so predictably began crafting lucrative bilateral
deals with pharmaceutical companies to secure their own domestic
supply of vaccines.
At the time of this presentation, more than 550 million vaccine
doses have been administered in over 150 countries. This figure belies
the great imbalance we are now witnessing in terms of the countries
that have a substantial portion of the population vaccinated and the
number of people getting doses in a single day. Globally, only 10
19
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economies account for 77% of vaccine doses administered thus far.
When we plot this on a map, it becomes all too clear that some places,
and especially the continent of Africa are being left behind in what
should have been the world’s most solidaristic vaccination drive. At
this rate, the poorest countries in the world may not achieve a critical
mass of inoculations for several more years.
The COVAX facility was the international mechanism intended
to facilitate, among other things, the distribution of doses to countries
that lacked adequate supply on their own. The idea behind COVAX
was to build a strong and unified pool of funds that would diversify the
portfolio of vaccine candidates available to all members of COVAX.
Ultimately, this would help fund and distribute vaccines to at least 20%
of populations in low- and middle-income countries.
At the time of this presentation, COVAX has so far delivered 33
million doses to 70 countries but it could have accomplished much
more. It did not because wealthy countries began “cutting to the front
of the queue” and negotiating their own deals with pharmaceutical
companies, paying more than what COVAX had to offer. That move
essentially crippled the world’s bargaining power with vaccine
makers. When you have only one negotiating partner with
pharmaceutical companies, you can essentially negotiate the terms of
that deal. When you have multiple negotiating partners and highincome countries entering the equation, lower income countries no
longer have that that leverage to negotiate favorable contractual terms.
We largely do not know what transpired in these bilateral vaccine
purchasing negotiations, and the fine print that became of deals that
countries struck with pharmaceutical companies. This information has
remained strictly confidential.
This secrecy has also had secondary nefarious effects. It has
exposed many countries in the Global South, who are also working to
negotiate deals bilaterally with pharmaceutical companies, to ‘highlevel bullying’ in the deal-making process. Reports have emerged of
countries having no choice but to agree to contracts with unfair or onesided liability clauses that essentially absolve vaccine makers of even
the most egregious forms of negligence. Secrecy undermined global
solidarity for pandemic response and recovery at a time when it was
needed most.
There has been a stream of piecemeal financing commitments in
order to help achieve the aims of COVAX, but significant shortfalls in
funding remain. Additionally, despite delays in the rollout of COVAX
vaccine distribution efforts to the poorest countries, some wealthy
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contributor-countries have bewilderingly opted to take vaccines out via
the mechanism, even though their own bilateral deals with vaccine
makers guaranteed them enough doses to fully vaccinate their
populations several times over. Here I am especially referring to my
own country, Canada, which notoriously opted to take millions of
doses out of COVAX in February 2021.
As a result, there are now even fewer jabs available for people
living in countries that are reliant on COVAX. This move might have
been understandable if all high income countries had agreed to pool
their vaccine financing commitments through COVAX, as originally
hoped. Under current conditions, however, with high-income countries
negotiating their own bilateral deals with vaccine makers, Canada’s
decision to withdraw doses from the COVAX facility is inexcusable.
The ability of countries to procure vaccines from COVAX is also
limited by the international rules that grant exclusive intellectual
property rights to pharmaceutical companies under the World Trade
Organization’s (WTO’s) Trade-Related Aspects of Intellectual
Property Rights (TRIPS) agreement. A waiver to the TRIPS
agreement, which is currently supported by over 100 WTO members
led by South Africa and India, calls for a temporary suspension of
intellectual property rights related to COVID-19 vaccines until the end
of the crisis. If we did have a waiver in place then it follows, at least
conceptually, that the number of manufacturers that could produce
vaccines could meaningfully increase. This is contingent on how much
money we invest to produce vaccine manufacturing sites around the
world, and of course how the original makers of vaccines, such as
Pfizer and Moderna, may be compelled to transfer technical know-how
to manufacturers in other parts of the world. The TRIPS agreement
nevertheless is a legal impediment to an equitable global pandemic
response that should operate on multiple fronts including but going
beyond “charitable” donations of doses.
Instead, we now must rely on the goodwill of pharmaceutical
companies to license their vaccines to a select handful of third party
manufacturers. Recent experiences expose this as a losing strategy. In
2020, for instance, the Astra-Zeneca vaccine was licensed to the Serum
Institute of India in hopes that the latter company would become the
biggest supplier of vaccines to COVAX. By spring 2021, however, as
Indians died in record numbers from an unrelenting outbreak of
COVID-19 across the country, the Indian government ordered the
Serum Institute to prioritize vaccination of the Indian population, and
in late May 2021, the Serum Institute acknowledged that it would not
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be able to fulfill timelines for vaccine exports to COVAX. Noting these
and other shortcomings in the global COVID-19 response, the WHO
Director General has called this observed lack of cooperation and
solidarity across nations a catastrophic moral failure. And there are at
least four reasons why he is right.
The first and most obvious reason is that vaccine inequity gives
the virus more opportunities to mutate into variants that can cause more
dangerous and transmissible versions of the COVID-19 disease.
Eventually, these variants of concern may spread and become the
dominant strain, particularly in localities that choose, against WHO
advice, to loosen public health measures and take their “foot off the
brakes” on effective non-pharmaceutical public health strategies such
as contact tracing, and robust, population-wide testing. The virus’
ongoing evolution means that no country can feel safe until every
country has taken precautions.
The second consequence of this profound vacuum of global
solidarity is that the global economy may take a much longer to reach
steady state because of an unnecessarily prolonged and divided
pandemic. By some estimates, if we fail to swiftly curb the pandemic,
we run the risk of losing as much as $9 trillion dollars in the global
economy – a cost that will be borne and felt in equal parts by all
countries.
The third consequence is that it has in some cases enabled
neocolonial and problematic manifestations of vaccine diplomacy. The
idea of using vaccines as a tool for diplomacy is not at all new and it
can sometimes even be a catalyst for peaceful interstate relations. In
the 1800s, for instance, an English physician known as Dr. Edward
Jenner discovered that the use of the cowpox virus could inoculate
humans against the smallpox virus. The smallpox vaccine Jenner
created not only entered widespread use in England, but was then
shipped over to France, where it became so successful as a public
health intervention that Napoleon Bonaparte swiftly mandated the
establishment of vaccine departments throughout the major cities of
the French Empire. Jenner later remarked in a letter to the National
Institute of France that the “sciences are never at war”. The statement
is especially significant considering that for the majority of the time
that vaccines were being shared between England and France, the two
countries were actually at war. But today, the manifestations of vaccine
diplomacy we are seeing have generally not been of the kind that can
help resolve conflict or tension between countries. In our polarized
world, Western countries, Russia and China have all resorted to
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vaccine sharing as a tool for soft power and statecraft, instead of as a
matter of collective responsibility, solidarity and international
rapprochement.1
What should fundamentally concern us all, however, is the
catastrophic failure to see how the virus will redraw borders around the
world. As governments begin to vaccinate entire populations, the next
step they may reach for is ensure that travel to their country is
contingent upon proof of inoculation. Imposing such barriers to the
entry of travelers that have only been vaccinated, or have only been
vaccinated with certain vaccines, will inevitably result in the exclusion
of vast swathes of people who no longer have the privilege of entering
a country because of the fact that they do not have a certain number of
doses of vaccine A or vaccine B or vaccine C. This is deeply
problematic from an global health equity and human rights
perspective.
So whether it is dose sharing through COVAX, technology
transfer, voluntary licensing, or the waiving international trade laws
that grant exclusive intellectual property rights, we need to pull out all
the stops to get vaccines to people everywhere in the world as soon as
humanly possible. The COVID-19 vaccine race is not about
vaccinating the population of just one country or vaccinating some
people quickly. It is about vaccinating the people of all countries as
soon as possible. Few examples in global health show as palpably as
the current pandemic how the fates of people in every country are
inextricably tied. A pandemic response underpinned by solidarity is
the only way to end this economic, health, and human rights
catastrophe. Thank you very much.

1. For those interested in learning more about the historical use of vaccines as a tool for
foreign diplomacy, I recommend reading works by Dr. Peter Hotez. See for instance: Peter J.
Hotez, “Vaccine Diplomacy”: Historical Perspectives and Future Directions, 8 PLOS
Neglected Tropical Diseases e2808 (2014).

